---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-192362"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T02:18:57.721359+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings

## Summary
- Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.
- Expects total restructuring charges of ~$8M, primarily severance, recognized in H1 2026; plan substantially complete by Q3 2026.
- Reaffirms FY 2026 AUCATZYL net product revenue guidance of $120M-$135M, up from $74M in 2025.
- Expects ~$15M annualized cost savings beginning in 2027; aims for positive gross margin in 2026.
- Clinical programs on track: CATULUS (pediatric ALL), LUMINA (lupus nephritis), BOBCAT (MS).

## SEC filing metadata
- accession: 0001193125-26-192362
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/0001193125-26-192362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/d113906d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-192362
- JSON: https://secwatch.observer/filing/0001193125-26-192362.json
- Plain text: https://secwatch.observer/filing/0001193125-26-192362.txt

## Key facts
- Restructurings & Charges
  Autolus Therapeutics plc announced a restructuring with charges of total restructuring charges of approximately $8 million, consisting primarily of employee severance and related costs affecting all areas of the business (approximately 13% of the Company’s workforce).
  - Type: restructuring
  - Charge: total restructuring charges of approximately $8 million, consisting primarily of employee severance and related costs
  - Affected area: all areas of the business
  - Headcount: approximately 13% of the Company’s workforce
  source text: Item 2.05 Costs Associated with Exit or Disposal Activities. On April 29, 2026, Autolus Therapeutics plc (the “Company”) announced its Board of Directors approved a plan to improve operational efficiency and reduce operating expenses. This plan will implement a reduction in force whereby the Company will eliminate approximately 13% of the Company’s workforce, inclusive of employee-related actions that began in the second half of 2025. The Company anticipates that it will complete the implementation of the plan by the third quarter of 2026. Affected employees will be offered separation benefits, including severance payments and, where applicable, temporary healthcare coverage assistance. The Company estimates that it will incur total expenses relating to the realignment of approximately $8 million, consisting of severance and termination-related costs. The Company expects to record a significant portion of these charges in the first half of 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000119312526192362/0001193125-26-192362-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.